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Edited by Laszlo NagyAbstract Aldehyde oxidase 1 (AOX1) is highly abundant in the
liver and oxidizes aldehydes thereby generating reactive oxygen
species. Enzymes involved in detoxiﬁcation of aldehydes are ex-
pressed in adipocytes and alter adipogenesis, therefore the func-
tional role of AOX1 in adipocytes was analyzed. AOX1 mRNA
was higher in visceral compared to subcutaneous human adipose
tissue but AOX1 protein was detected in both fat depots. AOX1
expression in adipocytes was conﬁrmed by immunohistochemis-
try and immunoblot. AOX1 was induced during adipocytic diﬀer-
entiation and was downregulated by fenoﬁbrate in diﬀerentiated
cells. Knock-down of AOX1 in preadipocytes led to impaired li-
pid storage and adiponectin release in the diﬀerentiated cells.
These data indicate that AOX1 is essential for adipogenesis
and may link energy and drug metabolism.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aldehyde oxidase 1 (AOX1) is a member of the molybde-
num iron–sulfur ﬂavoproteins and catalyzes the oxidation of
a variety of aldehydes and nitrogenous heterocylic xenobiotics
[1]. AOX1 has been mainly studied in pharmacokinetics and
has the ability to oxidize drugs including antitumor agents,
sedatives, antihypertensives and acyclovir to treat herpes virus
infections. Oxidation of these drugs may lead to their detoxiﬁ-
cation or to the activation of prodrugs like 5-ﬂuoro-2-pyrimid-
inone to 5-ﬂuorouracil [2]. Physiological substrates of AOX1
are not well described and may include indol, pyridoxal, nico-
tinamide and retinaldehyde [3]. Although typical substrates of
AOX1 are aromatic aldehydes, crotonaldehyde generated by
lipid peroxidation is also oxidized by this enzyme [3,4]. Alde-
hydes are highly reactive compounds and covalently bind to
protein or DNA and oxidation to their corresponding carbox-*Corresponding author. Fax: +49 941 944 7019.
E-mail address: christa.buechler@klinik.uni-regensburg.de (C.Buechler).
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(2-deoxy-beta-D-erythropentofuranosyl)-pyrimido[1,2-a]purine-
10(3H)-one (M1dG) is a DNA adduct arising from the reac-
tion of 2-deoxyguanosine with lipid peroxidation products
and AOX1 is involved in its metabolism to 6-oxo-M1dG that
is excreted by the kidney [7].
AOX1 is highly expressed in the human liver [8] and free
radicals generated by AOX1 during the metabolism of acetal-
dehyde are suggested to contribute to ethanol-induced liver in-
jury [3]. AOX1 is also induced in the steatotic liver of rats on a
high-fat diet and may protect the liver from the toxic eﬀects of
aldehydes, whereas an enhanced production of reactive oxygen
species (ROS) by this enzyme may contribute to liver ﬁbrosis
[4,9].
The aldo-keto reductase AKR1B7 catalyzes the conversion
of aldehydes and ketones to their corresponding alcohols
and is also expressed in adipocytes. AKR1B7 is reduced in
the adipose tissue of diet induced obese mice and overex-
pression in 3T3-L1 cells disturbs adipogenesis [10]. Fatty
aldehyde dehydrogenase (FALDH) is highly abundant in
the liver and oxidizes aliphatic and aromatic aldehydes to
their corresponding carboxylic acid and therefore is involved
in the detoxiﬁcation of exogenous and endogenous aldehydes
[11]. Recent work indicates that FALDH is expressed in adi-
pocytes and is induced during adipocytic diﬀerentiation. Ec-
topic expression of FALDH in adipocytes alleviates insulin
resistance induced by 4-hydroxynonenal, a major lipid per-
oxidation product related to oxidative stress [12]. Reactive
oxygen species (ROS) contribute to the pathogenesis of
obesity-associated insulin resistance [13,14] and are linked
to impaired adipogenesis and reduced lipid storage in white
adipose tissue. In addition, oxidative stress reduces the re-
lease of adiponectin, an adipocyte derived insulin sensitizer
[15].
AOX1 was suggested to signiﬁcantly contribute to endoge-
nous ROS production [6] and, in addition, is involved in cellu-
lar detoxiﬁcation reactions [3] but so far it has not been
analyzed whether this protein is expressed in adipocytes. Gene-
Chip experiments revealed that AOX1 is higher abundant in
visceral when compared to subcutaneous adipose tissue [16],
however, adipose tissue is composed of several diﬀerent cell
types. Therefore, we were interested in whether AOX1 isblished by Elsevier B.V. All rights reserved.
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enzyme may inﬂuence adipocyte function.2. Materials and methods
2.1. Culture media and reagents
TRIzol reagent was from GIBCO (Carlsbad, CA) and oligonucle-
otides were synthesized by Metabion (Planegg-Martinsried, Ger-
many). The PPARc antibody was from Acris (Hiddenhausen,
Germany) and the PPARa antibody from Abcam (Cambridge,
UK). AOX1 antibody and ﬂotillin-1 antibody were from BD Biosci-
ences (Heidelberg, Germany). Fatty acid synthase (FAS) and GAP-
DH antibodies were from New England Biolabs GmbH (Frankfurt,
Germany). Puriﬁed human preadipocytes and diﬀerentiated adipo-
cytes were ordered from BioCat (Heidelberg, Germany). 3T3-L1 cells
were cultivated as described [17]. The b-actin antibody, LPS (Esche-
richia coli serotype 055:B5), palmitic acid, oleic acid, linolic acid, Oil
Red O, RU486, GW9662, fenoﬁbrate and pioglitazone were ordered
from Sigma (Deisenhofen, Germany). The PPARa agonist WY14643
was from Calbiochem (Darmstadt, Germany). AOX1 human siRNA
(GCCAAUGCCUGUCUGAUUCtt, 83% identity to the mouse
gene) and Silencer Negative Control 1 siRNA were from Applied
Biosystems (Darmstadt, Germany) and the assay to determine triglyc-
erides, the siRNA Xtreme transfection reagent, the cytotoxicity detec-
tion kit and the LightCycler FastStart DNA Master SYBR Green I
were purchased from Roche (Mannheim, Germany). ELISAs for
mouse adiponectin and leptin were from R&D Systems (Wiesba-
den-Nordenstadt, Germany).
2.2. Adipose tissue
Paired samples of subcutaneous and visceral adipose tissues of 15
patients (13 males) were obtained from patients undergoing surgery
for colon carcinoma (6), cryptogenic liver cirrhosis (1), hepatocellu-
lar carcinoma (3), Klatskin tumor (1), Caroli disease (1), hyperne-
phroma (1), renal cell carcinoma (1) and living organ donation
(1). The mean age was 61.1 ± 15 years and the mean body mass in-
dex was 26.1 ± 3.5 kg/m2. The study protocol was approved by the
local ethics committee and was carried out in accordance with
the Helsinki guidelines and all patients gave written informed
consent.
2.3. Monitoring of gene expression by real-time RT-PCR
Real-time RT-PCR was performed as recently described and the
speciﬁcity of the PCRs was conﬁrmed by sequencing of the ampliﬁed
DNA fragments [18]. The primers for human AOX1 and human b-ac-
tin were used as described [18]. For human porphobilinogen deaminase
PBGD uni: 5 0-GAGTGATTCGCGTGGGTACC-3 0 and PDGB rev:
5 0-GGCTCCGATGGTGAAGCC-3 0 [19] were used. For mouse genes
the primers AOX1 uni: 5 0-TGGACCATGGAAACTCAACA-30 and
AOX1 rev: 5 0-CCAGAATCATCTACAGCACTGC-3 0, b-actin uni:
5 0-TGGAATCCTGTGGCATCCATG-3 0 and b-actin rev: 5 0-TAA-
AACGCAGCTCAGTAACAG-3 0, GAPDH uni: 5 0-TGTCC-
GTCGTGGATCTGAC-30 and GAPDH rev: 5 0-AGGGAGATGCT-
CAGTGTTGG-3 0, PPARa uni: 5 0-AACTGGATGACAGTGA
CATTTCC-30 and PPARa rev: 5 0-CCGAAGGTCCACCATTTTT-
3 0, PPARc uni: 5 0-TTATAGCTGTCATTATTCTCAGTGGAG-3 0
and PPARc rev: 5 0-GGGTGGGACTTTCCTGCTA-3 0 were used.
2.4. Immunohistochemistry (IHC)
Immunohistochemical studies for the expression of AOX1 utilized
an avidin–biotin peroxidase method with a 3,3 0-diaminobenzidine
(DAB) chromatogen. Four micrometers sections were cut from forma-
lin-ﬁxed and paraﬃn-embedded tissue. After deparaﬃnization for
10 min in xylol, tissue sections were rehydrated in descending ethanol
series. After antigen retrieval (microwave oven for 10 min at 250 W in
citrate buﬀer, pH 7.1) IHC was done using the ChemMate Kit
(DAKO, Glostrup, Denmark) and the monoclonal AOX1 antibody
according to the manufacturers protocol. IHC was carried out in a
NEXES immunostainer (Ventana, Tucson, AZ) following manufac-
turers instructions.2.5. SDS–PAGE and immunoblotting
The adipose tissue was solubilized in radioimmunoprecipitation as-
say (RIPA) lysis buﬀer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
5 mM EDTA, 0.05% [v/v] Nonidet P-40, 1% [v/v] DOC, 1% [v/v] Tri-
tonX-100 and 0.1% [v/v] SDS). Proteins were separated by SDS–
PAGE and were transferred to PVDF membranes (Bio-Rad, Ger-
many). Incubations with antibodies were performed in 1% BSA in
PBS, 0.1% Tween overnight. Detection of the immune complexes
was carried out with the ECL Western blot detection system (Amer-
sham Pharmacia, Deisenhofen, Germany).
2.6. Statistical analysis
Data are represented as mean ± S.D. (SPSS 15.0). Statistical diﬀer-
ences were analyzed by paired Students t-test and a value of
P < 0.05 was regarded as statistically signiﬁcant.3. Results
3.1. AOX1 mRNA and protein in adipose tissue
Total RNA prepared from subcutaneous and visceral adi-
pose tissue of ﬁve donors was used for real-time RT-PCR.
The mRNA expression of AOX1 normalized to the reference
gene b-actin (or porphobilinogen deaminase (PBGD)) was
1.3 ± 0.17 (0.4 ± 0.1 when PBGD was used) in subcutaneous
fat and 1.8 ± 0.5 (0.7 ± 0.3 when PBGD was used) in visceral
adipose tissue (P = 0.016) (P = 0.005 when PBGD was used)
(Fig. 1A). Immunoblot was performed with 20 lg protein from
subcutaneous and visceral adipose tissue of 10 diﬀerent donors
and the results of eight donors are shown in Fig. 1B. AOX1
protein expression was found to be higher in the visceral fat
of three probands, in three additional paired samples AOX1
protein was elevated in the subcutaneous fat depot and protein
was similar abundant in both depots of three probands. AOX1
protein was not detected in the adipose tissue of one donor.
3.2. Immunohistochemistry of AOX1 protein in adipose tissue
Adipose tissue is composed of several cell types and there-
fore immunohistochemistry was performed to ﬁnd out whether
adipocytes express AOX1 protein. Whereas no staining was
detected in subcutaneous adipose tissue of the donor shown
in Fig. 2 (consistent with data revealed by immunoblot in
Fig. 1B), in visceral adipose tissue AOX1 was detected in the
cytoplasma of adipocytes (Fig. 2B). Furthermore, AOX1 was
localized in the cytoplasma of mesothelial cells (Fig. 2C). As
positive control liver tissue was also stained with AOX1 anti-
body (Fig. 2D). Immunohistochemistry using either the ﬁrst
or the second antibody performed in parallel revealed no stain-
ing (not shown).
3.3. Expression of AOX1 in pre- and mature-adipocytes
AOX1 protein was detected by immunoblot in adipocytes
that were puriﬁed from subcutaneous tissue of three diﬀerent
donors. For comparison, cell lysate from HepG2 cells was also
analyzed on the same immunoblot (Fig. 3A). Preadipocytes
and the respective in vitro diﬀerentiated mature adipocytes
from the subcutaneous adipose tissue of three diﬀerent donors
were also analyzed by immunoblot. AOX1 protein was not de-
tected in preadipocytes but was strongly induced in mature
cells. A similar regulation was found for b-actin, GAPDH
and ﬂotillin-1 (Fig. 3B). Therefore, equal loading of the indi-
vidual lanes was demonstrated by Coomassie staining of the
membrane.
Fig. 1. AOX1 mRNA and protein expression in subcutaneous and visceral adipose tissue. (A) AOX1 mRNA was determined in paired samples of
subcutaneous (sc) and visceral (vis) adipose tissue of ﬁve probands by real-time RT-PCR. For normalization b-actin or PBGD mRNA levels were
used (*P < 0.05). (B) AOX1 and b-actin were analyzed by immunoblot in paired samples of subcutaneous (sc) and visceral (vis) adipose tissue of eight
probands.
Fig. 2. Immunohistochemical staining using a monoclonal AOX1 antibody. (A) Staining of subcutaneous adipose tissue with AOX1 antibody. (B)
Cytoplasmic expression of AOX1 in visceral adipose tissue. (C) AOX1 staining of mesothelial cells. (D) Normal liver tissue as positive control was
also stained (40-fold magniﬁcation).
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Because the 3T3-L1 mouse adipocytic cell line is often used
for in vitro studies, the expression of AOX1 was also investi-
gated during adipocytic diﬀerentiation in these cells. Whereas
preadipocytes had a very low expression of AOX1, in 2 d dif-
ferentiated cells AOX1 was induced and was not further upreg-
ulated in 3, 7 and 9 d diﬀerentiated cells (Fig. 3C). AOX1
mRNA was nearly four-fold higher in 2 d diﬀerentiated cells
when compared to preadipocytes (Fig. 3D) and doubled from
days 2 to 6. Fatty acid synthase (FAS) protein was also upreg-
ulated in the 2 d diﬀerentiated cells, whereas an induction of
PPARc was not observed before day 3 after initiation of diﬀer-
entiation (Fig. 3C) and a similar regulation was observed for
PPARc mRNA expression (Fig. 3E). Whereas the expression
of PPARc in 3T3-L1 cells has been intensively studied, data
on PPARa are sparse. Therefore, PPARa mRNA was deter-mined in 3T3-L1 cells during diﬀerentiation and PPARa
mRNA steadily increased until day 6 of diﬀerentiation where
it was nearly 26-fold higher than in the preadipocytes but
was then reduced by about 50% in the 9 d diﬀerentiated cells
(Fig. 3F). PPARa protein was hardly detectable by immuno-
blot and was found increased in the 2 d diﬀerentiated cells
when compared to preadipocytes (Fig. 3C). Adiponectin, an
insulin-sensitizing protein that is induced by PPARc activation
[20], was also measured in the supernatant of the cells and is
induced in the 6 and 9 d diﬀerentiated cells (Fig. 3G).
It was also analyzed whether diﬀerentiation under inﬂamma-
tory conditions (LPS) or in the presence of elevated amounts
of free fatty acids may inﬂuence AOX1 protein in these cells.
Diﬀerentiation was induced in 3T3-L1 cells and 2 d later
LPS (10 ng/ml), palmitic acid (PA), oleic acid (OA) or linolic
acid (LA) (200 lM or 400 lM) were added and medium was
Fig. 3. AOX1 protein in preadipocytes and mature cells. (A) AOX1 and b-actin were investigated in primary human subcutaneous adipocytes from
three diﬀerent donors and in HepG2 cells. (B) Preadipocytes (pre) and the corresponding mature (mat) adipocytes were obtained from the
subcutaneous adipose tissue of three donors and analyzed for AOX1, b-actin, ﬂotillin-1 and GAPDH by immunoblot. Coomassie stained membrane
is shown conﬁrming equal loading of the gel. (C) AOX1, PPARc, FAS, PPARa, GAPDH and b-actin were determined in the 3T3-L1 adipocytic cell
line in preadipocytes (pre) and in 2, 3, 7 and 9 d diﬀerentiated adipocytes and a representative result of three (two for PPARa) independent
experiments is shown. (D) AOX1 mRNA normalized to GAPDH mRNA during adipogenic diﬀerentiation is shown. (E) PPARc mRNA expression
normalized to GAPDH mRNA in preadipocytes and during adipogenic diﬀerentiation is shown. (F) PPARa mRNA expression normalized to
GAPDH mRNA in preadipocytes and during adipogenic diﬀerentiation is shown. (G) Adiponectin in the supernatant of 3T3-L1 cells during
diﬀerentiation. (H) AOX1 in 3T3-L1 cells diﬀerentiated in the presence of LPS. (I) Diﬀerentiation was induced in 3T3-L1 cells and 2 d later palmitic
acid (PA), oleic acid (OA) or linolic acid (LA) (200 lM or 400 lM) were added and medium was changed at day 4 and 7. AOX1 and b-actin were
analyzed by immunoblot in the 9 d diﬀerentiated 3T3-L1 cells.
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immunoblot in the 9 d diﬀerentiated 3T3-L1 cells and, whereas
200 lM PA did not inﬂuence AOX1 protein levels, AOX1 was
reduced in 3T3-L1 diﬀerentiated with 400 lM PA (Fig. 3I).
LPS, oleic acid and linolic acid did not alter AOX1 protein
(Fig. 3H and I).
3.5. Regulation of AOX1 in diﬀerentiated 3T3-L1 mouse
adipocytes by fenoﬁbrate and pioglitazone
In addition, the inﬂuence of the antidiabetic drug pioglitaz-
one, a PPARc agonist, and the antihyperlipidemic drug fenof-
ibrate, a PPARa agonist, were analyzed. Mature adipocytes
were treated with fenoﬁbrate (10 and 50 lM) for 24 h andAOX1 protein was reduced by 50 lM fenoﬁbrate (Fig. 4A).
When the cells were preincubated for 1 h with 10 lM
RU486, a PPARa antagonist, fenoﬁbrate-mediated suppres-
sion of AOX1 was less pronounced indicating that PPARa is
at least in part required for this eﬀect (Fig. 4A). To further
provide evidence that PPARa is important for AOX1 suppres-
sion the diﬀerentiated adipocytes were incubated with 20 lM
WY14643, a speciﬁc PPARa agonist, for 24 h. AOX1 was sup-
pressed and preincubation with 10 lM RU486 rescued AOX1
protein abundance in WY14643 treated cells (Fig. 4A). Fatty
acid synthase protein abundance was determined as a PPARa
regulated protein [21] and was downregulated by fenoﬁbrate
and WY14643 (Fig. 4A). Adiponectin was also determined in
Fig. 4. Regulation of AOX1 by pioglitazone, fenoﬁbrate and eﬀect of AOX1 knock-down in 3T3-L1 cells. (A) Diﬀerentiated 3T3-L1 cells were
stimulated with fenoﬁbrate, RU486 or both or with WY14643, RU486 or both and AOX1, FAS and b-actin were determined by immunoblot. (B)
Adiponectin was measured in the supernatants of 3T3-L1 cells treated with fenoﬁbrate, RU486 or both. (C) Leptin was measured in the supernatants
of 3T3-L1 cells treated with fenoﬁbrate, RU486 or both. (D) Diﬀerentiated 3T3-L1 cells were stimulated with pioglitazone (7.5 and 12.5 lM PG) for
24 h and AOX1 and b-actin were determined by immunoblot. The cells were also treated with 3.75 lM pioglitazone, GW9662 or both and AOX1 was
analyzed. (E) Adiponectin was determined in the supernatant of the pioglitazone treated cells. (F) AOX1, PPARc and b-actin protein in 3T3-L1
preadipocytes treated with AOX1 siRNA (AOX si) or control siRNA (Control si) and analyzed at day 9 after initiation of diﬀerentiation. (G) Knock-
down of AOX1 was performed in preadipocytes and lipid accumulation in the cells was determined by Oil Red O staining in 9 d diﬀerentiated 3T3-L1
cells (10-fold magniﬁcation). (H) Triglycerides were determined at day 9 after initiation of diﬀerentiation in 3T3-L1 cells treated with AOX1 siRNA
(AOX si) or control siRNA (Control si) at day 0, day 3 or day 6 of diﬀerentiation. (I) Knock-down of AOX1 or transfection with control siRNA was
performed in preadipocytes (d0), 1 d (d1), 3 d (d3) and 7 d (d7) diﬀerentiated cells and adiponectin was determined at day 9 in all supernatants. (J)
Lactate dehydrogenase (LDH) was determined at day 9 after initiation of diﬀerentiation in 3T3-L1 cells treated with AOX1 siRNA (AOX si) or
control siRNA (Control si) at day 0, day 3 or day 6 of diﬀerentiation (*P < 0.05).
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lease was 25.7 ± 3.8 ng/ml in control cells and 26.4 ± 3.3 ng/
ml in 3T3-L1 cells treated with RU486 alone. Fenoﬁbrate re-
duced adiponectin to 10.6 ± 3.0 ng/ml (P = 0.003 compared
to controls) and similar levels were detected in cells treated
with fenoﬁbrate and RU486 with 9.8 ± 1.9 ng/ml (P = 0.01
versus control) (Fig. 4B). Bezaﬁbrate was described to sup-
press leptin mRNA expression [22] and therefore leptin was
also measured in these supernatants. Leptin was
34.9 ± 4.6 pg/ml in control cells and 29.1 ± 2.8 pg/ml in
RU486 treated adipocytes. Fenoﬁbrate reduced leptin to
16.5 ± 1.9 pg/ml (P = 0.015 when compared to control cells)
and fenoﬁbate-mediated suppression of leptin release was
abrogated by RU486 with 31.2 ± 1.4 pg/ml leptin (Fig. 4C).
Diﬀerentiated 3T3-L1 cells were also stimulated with pioglit-
azone (3.75, 7.5 and 12.5 lM) and AOX1 was reduced by all
concentrations used. The PPARc agonist GW9662 (4 and
8 nM) did not abrogate AOX1 repression by 3.75 lM pioglit-
azone indicating that this eﬀect was independent of PPARc
activity (Fig. 4D). As a positive control adiponectin was deter-
mined and was found induced by the PPARc agonist and this
eﬀect was abrogated by GW9662 as expected [23] (Fig. 4E).
3.6. Knockdown of AOX1 in 3T3-L1 adipocytes impairs
adipogenesis and reduces adiponectin release
3T3-L1 cells were treated with AOX1 siRNA or a control
siRNA (100 nM for each siRNA), diﬀerentiation was induced
and 9 d later AOX1 protein was found signiﬁcantly reduced,
whereas PPARc was not altered (Fig. 4F). Lipid accumulation
in these cells was investigated by Oil Red O staining and was
found to be reduced (Fig. 4G). Triglycerides were determined
in 3T3-L1 cells where AOX1 siRNA or control siRNA was
added at day 0 (preadipocytes), at day 3 or at day 6 of diﬀer-
entiation in the 9 d diﬀerentiated cells. Triglycerides were sim-
ilar in all 3T3-L1 cells treated with control siRNA but were
about 30% lower when AOX1 siRNA was added at day 0 or
day 3 (Fig. 4H). Treatment of the cells with siRNA at day 6
did not alter cellular triglycerides (Fig. 4H). Adiponectin is in-
duced in mature cells and was also measured. To do so, 3T3-
L1 preadipocytes (day 0) were treated with AOX1 siRNA or
control siRNA and adiponectin was determined 9 d later.
When adiponectin in control cells was set to 100%, adiponectin
was reduced to 51.4 ± 6.1% (P = 0.003) (Fig. 4I). Transfection
with the siRNAs was also performed at day 1, 3 and 7 after
induction of diﬀerentiation and adiponectin was measured at
day 9. AOX1 siRNA treated cells transfected at day 1 had
65.0 ± 9.5% (P = 0.012) and at day 3 78.5 ± 4.7% (P = 0.008)
adiponectin compared to cells transfected with control siRNA.
3T3-L1 cells transfected at day 7 after initiation of diﬀerentia-
tion released similar levels of adiponectin (97.1 ± 10.0%,
P = 0.4) as cells transfected with the control siRNA (Fig. 4I).
To exclude that reduced adiponectin release is secondary to
higher cell death in AOX1 siRNA treated cells, lactate dehy-
drogenase was measured and was similar in the supernatants
of the cells (Fig. 4J).4. Discussion
AOX1 catalyzes the oxidation of aldehydes to their corre-
sponding carboxylic acids [2] and, whereas its physiologicalrole is largely unclear, the involvement of AOX1 in the catab-
olism of various xenobiotics has been extensively studied [2].
AOX1 is most abundant in the liver, the main organ for detox-
iﬁcation of drugs [2]. Enzymes that detoxify aldehydes are also
synthesized in adipocytes and inﬂuence adipogenesis [10,12].
Therefore, it was analyzed whether AOX1 is expressed in adi-
pose tissue and/or adipocytes. AOX1 mRNA was detectable in
adipose tissue and was found to be higher expressed in visceral
compared to subcutaneous adipose tissue of the same donor. A
recent study investigating diﬀerential gene expression in these
fat depots by GeneChip experiments also found a higher abun-
dance of AOX1 mRNA in omental fat [16]. However, AOX1
protein levels were highly variable when subcutaneous and vis-
ceral adipose tissues of 10 diﬀerent donors were compared.
Individual diﬀerences in aldehyde oxidase activity were also
described in the liver of humans and monkeys [24] indicating
that AOX1 protein abundance and activity may be regulated
by so far unknown mechanisms. Immunohistochemistry re-
vealed that adipocytes express AOX1 and this was conﬁrmed
by immunoblot using puriﬁed human adipocytes. AOX1 was
not expressed or was low abundant in human preadipocytes
and was highly induced in mature adipocytes and a similar reg-
ulation was found for b-actin. AOX1 was also low abundant in
preadipocytes and was induced in diﬀerentiated 3T3-L1 cells
indicating that regulation of AOX1 during diﬀerentiation is
similar in primary human and 3T3-L1 mouse cells. AOX1
mRNA in the cell line was strongly induced 2 d after the induc-
tion of diﬀerentiation. The AOX1 promoter contains Sp1/Sp3
binding sites [25] and Sp1/Sp3 are activated in 3T3-L1 cells
shortly after the induction of diﬀerentiation [26] making these
transcription factors interesting candidates that may be in-
volved in the early induction of AOX1 expression.
Diﬀerentiation of 3T3-L1 cells in the presence of LPS or the
free fatty acids oleic acid and linolic acid did not inﬂuence
AOX1 protein, whereas 400 lM palmitic acid reduced
AOX1. Because saturated and monounsaturated free fatty
acids do not aﬀect diﬀerentiation and similar amounts of tri-
glycerides are accumulated in the cells [27], reduced abundance
of AOX1 in cells diﬀerentiated in the presence of 400 lM pal-
mitic acid is at least not explained by disturbed adipogenesis.
The eﬀects of the polyunsaturated linolic acid on adipogenesis
have not been investigated to our knowledge so far but lipid
storage seems not to be altered in these cells (not shown).
When AOX1 was reduced by siRNA in preadipocytes the
fully diﬀerentiated 3T3-L1 cells accumulated less triglycerides
and, in addition, the release of the antidiabetic protein adipo-
nectin [28] was reduced. AOX1 knock-down in 3 d diﬀerenti-
ated cells also lowered cellular triglycerides and adiponectin
release. In more (6 d or 7 d) diﬀerentiated cells reduction of
AOX1 did not aﬀect adiponectin secretion or triglyceride accu-
mulation that was measured in 9 d diﬀerentiated cells. There-
fore, reduced adiponectin and triglyceride storage were most
likely secondary to impaired diﬀerentiation and not a direct ef-
fect of low AOX1 protein.
Adipocytes are a major cell target for PPARc agonists like
the antidiabetic thiazolidinediones [23,29]. PPARc is expressed
at high levels in adipose tissue and controls adipogenesis and
insulin sensitivity [23]. Pioglitazone downregulated AOX1 in
diﬀerentiated adipocytes but this eﬀect was independent of
PPARc. Despite lower AOX1 in pioglitazone treated cells
adiponectin was induced [30] further indicating that reduced
AOX1 in diﬀerentiated cells does not directly inﬂuence adipo-
J. Weigert et al. / FEBS Letters 582 (2008) 2965–2972 2971nectin release. Fenoﬁbrate, an agonist of PPARa, was demon-
strated to suppress AOX1 protein in hepatocytes and AOX1
activity in human liver [18,31] and this drug also reduced
AOX1 protein in diﬀerentiated 3T3-L1 cells. Fenoﬁbrate
(300 mg/kg/d) treatment for 2 weeks decreased systemic adipo-
nectin in db/db mice [32] and adiponectin was also lower in the
3T3-L1 cells treated with fenoﬁbrate in the current study. The
eﬀect of fenoﬁbrate on adiponectin release may also depend on
the state of diﬀerentiation because treatment of 4 d diﬀerenti-
ated 3T3-L1 cells with fenoﬁbrate even induced adiponectin re-
lease [33]. Although AOX1 suppression was abrogated by a
PPARa agonist, adiponectin release was still diminished.
Therefore, suppression of adiponectin release by fenoﬁbrate
seems not to depend on the activation of PPARa and, in addi-
tion, this ﬁnding further conﬁrms that AOX1 abundance does
not directly inﬂuence adiponectin release.
AOX1 protein in preadipocytes and during early diﬀerentia-
tion seems to be essential for adipogenesis but additional stud-
ies have to be performed to clarify the molecular mechanisms
of this observation. AOX1 may produce ROS and, whereas
elevated ROS may cause insulin resistance [8,34] lower levels
seem to be essential for adipogenesis [35]. Furthermore,
AOX1 catalyzes the oxidation of vitamin A aldehyde to reti-
noic acid which inﬂuences adipocyte diﬀerentiation and sur-
vival, with high doses inhibiting and low doses promoting
adipogenesis of preadipocytes in vitro [36,37]. Aldehydes gen-
erated by lipid peroxidation may also impair the diﬀerentiation
of adipocytes and detoxiﬁcation by AOX1 may be beneﬁcial
[5,38].
The so far best characterized role of AOX1 is the catabolism
or activation of various xenobiotics [2]. Although it is well
known that lipophilic drugs are stored in adipose tissue and
thereby display an altered pharmacokinetic proﬁle in patients
with elevated adipose tissue [39], studies on the expression of
drug metabolizing enzymes in adipocytes are rare [40]. The
abundance of AOX1 in adipocytes and its regulation by
PPARa agonists may indicate an important role of AOX1 in
adipose tissue biology that may be inﬂuenced by drugs.
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